

13 December 2023

## **Unaudited Q4 FY23 revenue to date takes total FY23 revenue to over \$20m, up 130% on FY22**

### **Highlights:**

- **Unaudited group revenues of ~\$5.942m in Q4 to date; already a 131% increase on the prior-year comparative period (PCP)**
- **Q4 sales to date take total FY23 to over ~\$20m – a major milestone for Melodiol and a 130% increase on total FY22 revenue (total FY22 revenue: \$8.69m)**
- **Additional growth initiatives being progressed across business divisions to drive further sales – more revenue expected to materialise in coming weeks**
- **FY23 growth trajectory validates Company’s stated strategy of high growth via strategic acquisitions**

**Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’)** is pleased to advise that it has generated unaudited revenue of ~\$5.942m to date in Q4 FY23, further underlining the Company’s strong growth trajectory throughout the 12 month period.

Preliminary revenues in the quarter to-date already reflect a 131% increase on the prior corresponding period (Q4 FY22: \$2.571m).

Total unaudited FY23 revenue has also exceeded ~\$20m, highlighting another major milestone for Melodiol and a 130% increase on total FY22 revenue (total unaudited FY22 revenue: \$8.69m).

Q4 FY23 results have been driven by sales from Company’s wholly-owned Canadian subsidiary, Mernova Medicinal Inc. (‘Mernova’), as well as its 100%-owned operating division, Health House International (‘HHI’ or ‘HHI International’). The projected annual revenue result further validates Melodiol’s growth-by-acquisition strategy.

The Company is confident that each division will continue to generate additional sales through the course of December 2023. Melodiol remains increasingly focused on its stated strategy of maintaining high revenue growth across the group, with an emphasis on cost management as it targets a cash-flow breakeven position.

### **Management commentary:**

**CEO and Managing Director, Mr William Lay said:** *“We are very pleased to provide this update on Q4 FY23 revenue, which further highlights the Company’s rapid sales trajectory and validates Melodiol’s strategy of growth via strategic acquisition.*

*“Over the course of FY23, the Company has been focused on optimising operations to deliver high revenue opportunities while maintaining a focus on costs. During Q3 FY23, Melodiol delivered on this goal, which lays a strong foundation for FY24. We look forward to providing further updates on Q4 FY23 sales over the coming weeks as additional revenue materialises.”*

**-Ends-**

## Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

## Investor Enquiries

Melodiol Global Health Limited

E: [info@cresopharma.com](mailto:info@cresopharma.com)

P: +61 (0) 497 571 532

## About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

## Melodiol offices:

**Australia:** Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Canada:** 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

## Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.